# EDGAR Filing Document

**Accession Number:** 0001711933
**File Stem:** 0001104659-23-027359
**Filing Date:** 2023-3
**Character Count:** 8659
**Document Hash:** 730619c15f36b7b074b8e0766e490996
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-027359.hdr.sgml**: 20230301

**ACCESSION NUMBER**: 0001104659-23-027359

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20230227

**FILED AS OF DATE**: 20230301

**DATE AS OF CHANGE**: 20230301

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Kamocsay Jennifer
- **CENTRAL INDEX KEY:** 0001967264

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40344
- **FILM NUMBER:** 23694256

**MAIL ADDRESS:**
- **STREET 1:** 100 CAMPUS DRIVE
- **STREET 2:** 6TH FLOOR
- **CITY:** MARLBOROUGH
- **STATE:** MA
- **ZIP:** 01762
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Akoya Biosciences, Inc.
- **CENTRAL INDEX KEY:** 0001711933
- **STANDARD INDUSTRIAL CLASSIFICATION:** LABORATORY ANALYTICAL INSTRUMENTS [3826]
- **IRS NUMBER:** 475586242
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 100 CAMPUS DRIVE
- **STREET 2:** 6TH FLOOR
- **CITY:** MARLBOROUGH
- **STATE:** MA
- **ZIP:** 01762
- **BUSINESS PHONE:** 855.896.8401

**MAIL ADDRESS:**
- **STREET 1:** 100 CAMPUS DRIVE
- **STREET 2:** 6TH FLOOR
- **CITY:** MARLBOROUGH
- **STATE:** MA
- **ZIP:** 01762

## Exhibit 24.1

**Exhibit 24.1**

**LIMITED POWER OF ATTORNEY FOR**

**SECTION 16 REPORTING OBLIGATIONS**

Know all by these presents, that the undersigned hereby makes, constitutes and appoints Brian McKelligon, Branden Steinberg and Joseph Driscoll as the undersigned's true and lawful attorney-in-fact, with full power and authority as hereinafter described on behalf of and in the name, place and stead of the undersigned to:

&nbsp;&nbsp;&nbsp;&nbsp;(1) with respect to the equity
securities of Akoya Biosciences, Inc., a Delaware corporation (the "  ***Company*** "), prepare, execute, acknowledge,
deliver and file with the United States Securities and Exchange Commission (the "  ***SEC*** "), any national securities
exchanges and the Company, (i) a Form ID, and any amendments thereto, Update Passphrase Confirmation, and any other documents
necessary or appropriate to obtain codes and passwords enabling the undersigned to make electronic filings with the SEC, and (ii) any
and all reports (including Forms 3, 4, and 5) and any amendments thereto, as considered necessary or advisable under Section 16(a) of
the Securities Exchange Act of 1934 and the rules and regulations promulgated thereunder, as amended from time to time (the "  ***Exchange Act*** ");

&nbsp;&nbsp;&nbsp;&nbsp;(2) seek or obtain, as the undersigned's
representative and on the undersigned's behalf, information regarding transactions in the Company's equity securities from any
third party, including the Company and any brokers, dealers, employee benefit plan administrators and trustees, and the undersigned hereby
authorizes any such person to release any such information to the undersigned and approves and ratifies any such release of information;
and

&nbsp;&nbsp;&nbsp;&nbsp;(3) perform any and all other acts which in the discretion of such attorney-in-fact are necessary or desirable
for and on behalf of the undersigned in connection with the foregoing.

The undersigned acknowledges that:

&nbsp;&nbsp;&nbsp;&nbsp;(1) this Power of Attorney authorizes, but does not require, such attorney-in-fact to act in his or her discretion
on information provided to such attorney-in-fact without independent verification of such information;

&nbsp;&nbsp;&nbsp;&nbsp;(2) any documents prepared and/or executed by such attorney-in-fact on behalf of the undersigned pursuant
to this Power of Attorney will be in such form and will contain such information and disclosure as such attorney-in-fact, in his or her
discretion, deems necessary or desirable;

&nbsp;&nbsp;&nbsp;&nbsp;(3) neither the Company nor such
attorney-in-fact assumes (i) any liability for the undersigned's responsibility to comply with the requirement s of Section 16
of the Exchange Act, (ii) any liability of the undersigned for any failure to comply with such requirements, or (iii) any obligation
or liability of the undersigned for profit disgorgement under Section 16(b) of the Exchange Act; and

&nbsp;&nbsp;&nbsp;&nbsp;(4) this Power of Attorney does
not relieve the undersigned from responsibility for compliance with the undersigned's obligations under Section 16 of the
Exchange Act, including without limitation the reporting requirements under Section 16 of the Exchange Act.

The undersigned hereby gives and grants the foregoing attorneys-in-fact, and each of them, full power and authority to do and perform any and every act and thing whatsoever requisite, necessary or appropriate to be done in and about the foregoing matters as fully to all intents and purposes as the undersigned might or could do if present, with full power of substitution and re-substitution, hereby ratifying and confirming all that such attorney-in-fact, or his or her substitute or substitutes, shall lawfully do or cause to be done by authority of this Power of Attorney.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file reports (including Forms 3, 4 and 5) under Section 16 of the Exchange Act with respect to the undersigned's transactions in equity securities of the Company, unless earlier revoked by the undersigned in a signed writing delivered to such attorney-in-fact.

*[Signature page follows.]*

**In Witness Whereof**, the undersigned has caused this Power of Attorney to be executed as of this 27 day of February, 2023.

---

| |
|:---|
| /s/ Jennifer Kamocsay |
| Jennifer Kamocsay |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Kamocsay Jennifer<br><sub>(Last) (First) (Middle)</sub><br>100 CAMPUS DRIVE, 6TH FLOOR<br><sub>(Street)</sub><br>MARLBOROUGH, MA 01752<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Akoya Biosciences, Inc. [ AKYA ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2023-02-27 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_General Counsel_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| No securities are beneficially owned. | 0 | D |  |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |

---

**Remarks:**
Exhibit 24.1 Power of Attorney

**Signature:** /s/ Jennifer Kamocsay, by Brian McKelligon, as Attorney-in-Fact  
**Date:** 2023-03-01

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**